잠시만 기다려 주세요. 로딩중입니다.

Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy

Immune Network 2020년 20권 1호 p.8 ~ 8
 ( Kim Kyung-Hwan ) - Korea Advanced Institute of Science and Technology Graduate School of Medical Science and Engineering

 ( Kim Chang-Gon ) - Korea Advanced Institute of Science and Technology Graduate School of Medical Science and Engineering
신의철 ( Shin Eui-Cheol ) - Korea Advanced Institute of Science and Technology Graduate School of Medical Science and Engineering

Abstract


Immune checkpoint blockade targeting PD-1 and PD-L1 has resulted in unprecedented clinical benefit for cancer patients. Anti-PD-1/PD-L1 therapy has become the standard treatment for diverse cancer types as monotherapy or in combination with other anti-cancer therapies, and its indications are expanding. However, many patients do not benefit from anti-PD-1/PD-L1 therapy due to primary and/or acquired resistance, which is a major obstacle to broadening the clinical applicability of anti-PD-1/PD-L1 therapy. In addition, hyperprogressive disease, an acceleration of tumor growth following anti-PD-1/PD-L1 therapy, has been proposed as a new response pattern associated with deleterious prognosis. Anti-PD-1/PD-L1 therapy can also cause a unique pattern of adverse events termed immune-related adverse events, sometimes leading to treatment discontinuation and fatal outcomes. Investigations have been carried out to predict and monitor treatment outcomes using peripheral blood as an alternative to tissue biopsy. This review summarizes recent studies utilizing peripheral blood immune cells to predict various outcomes in cancer patients treated with anti-PD-1/PD-L1 therapy.

키워드

Blood; Biomarkers; PD-1 receptor; Programmed cell death 1 ligand 1; Prognosis; Adverse drug event
원문 및 링크아웃 정보
  
등재저널 정보